GlassScriptPhysician profile
Alok Jain
NPI 1285630095
$64,137.22
in general payments reported to CMS, 2019-2025
36 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $12K · 2021: $15K · 2022: $1,189 · 2023: $1,247 · 2024: $976 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,395 · Food and Beverage: $4,417 · Travel and Lodging: $1,316 · Education: $31.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,395.00 |
| Food and Beverage | $4,416.88 |
| Travel and Lodging | $1,315.87 |
| Education | $31.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31,146.21 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $13,293.59 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $10,654.70 | 2024-2025 | Cobenfy |
| Abbvie INC. | $3,319.20 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $860.56 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $639.00 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $603.77 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $538.25 | 2019-2025 | Uzedy |
| Lundbeck LLC | $379.43 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $362.94 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $362.78 | 2019-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Corium, LLC | $289.40 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $270.85 | 2019-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $263.48 | 2019-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $184.77 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $142.36 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $124.00 | 2019-2020 | |
| Tris Pharma INC | $102.23 | 2019-2023 | Dyanavel Xr |
| Eisai INC. | $102.02 | 2020-2021 | |
| Axsome Therapeutics, INC. | $80.66 | 2022-2023 | Auvelity |
| Shire North American Group INC | $54.62 | 2019 | |
| Harmony Biosciences LLC | $41.71 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $37.91 | 2019-2025 | Rejoyn |
| Almatica Pharma LLC | $30.61 | 2021 | |
| Acadia Pharmaceuticals INC | $28.76 | 2019-2020 | |
| Novo Nordisk INC | $26.44 | 2020-2023 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $25.99 | 2021 | |
| Braintree Laboratories, INC. | $25.57 | 2019 | |
| Collegium Pharmaceutical, INC. | $22.28 | 2025 | Jornay Pm |
| Neuronetics, INC. | $21.06 | 2020 | |
| Orexo US, INC. | $18.34 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.23 | 2022 | |
| Braeburn INC. | $18.12 | 2025 | Brixadi |
| Neos Therapeutics, LP | $17.00 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.81 | 2022 | |
| Alfasigma USA, INC. | $14.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.